A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

NCT02708095 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

314

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Baricitinib
DRUG: Placebo

Sponsor

Eli Lilly and Company